A phase I open-label dose-escalation study to assess the safety and tolerability of AT7519M a selective small molecule inhibitor of cyclin-dependent kinases in patients with advanced solid malignancies
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2009
At a glance
- Drugs AT 7519 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Astex Therapeutics
- 22 Apr 2009 Results presented at AACR 2009.
- 28 Jun 2006 New trial record.